Changes of peripheral blood ISGs and their relationship with curative effect of interferon therapy in patients with HBV infection

doi:10.3877/cma.j.issn.2095-2015.2024.04.011

Abstract

Abstract:

Objective

To explore the changes of peripheral blood interferon-stimulated genes (ISGs) and their relationship with curative effect of interferon therapy in patients with hepatitis B virus (HBV) infection.

Methods

A total of 80 patients with HBV infection and 80 healthy controls in Daxing Teaching Hospital of Capital Medical University were enrolled as HBV group and control group between April 2018 and May 2023, respectively. The mRNA levels of myxovirus resistance protein A (MxA), ubiquitin-specific protease 18 (USP18) and suppressors of cytokine signaling 3 (SOCS3) in peripheral blood were compared between the two groups. The patients in the HBV group were treated with recombinant human interferon α-2b for 24 weeks. According to interferon response, they were divided into response group (n=38) and non-response group (n=42). The relationship between peripheral blood indexes and interferon response was analyzed by Logistic regression analysis, and changes of MxA mRNA, USP18 mRNA and SOCS3 mRNA before and after interferon treatment in the HBV group were observed.

Results

Before treatment, level of peripheral blood MxA mRNA in the HBV group was lower than that in the control group, while levels of USP18 mRNA and SOCS3 mRNA were higher than those in the control group (P<0.05). Before treatment, level of peripheral blood MxA mRNA in the response group was higher than that in the non-response group, while levels of USP18 mRNA and SOCS3 mRNA were lower than those in the non-response group (P<0.05). Logistic regression analysis showed that high expressions of USP18 mRNA and SOCS3 mRNA were risk factors of interferon non-response, while high expression of MxA mRNA was a protective factor of interferon response. Before treatment, after 2 weeks, 12 weeks and 24 weeks of treatment, level of peripheral blood MxA mRNA in the interferon response group was higher than that in the non-response group, while levels of USP18 mRNA and SOCS3 mRNA were lower than those in the non-response group (P<0.05).

Conclusion

In the treatment of HBV infection with interferon, interferon response effect is better in those with high expression of MxA and low expressions of USP18 and SOCS3.

Key words: Hepatitis B virus, Interferon, Interferon-stimulated genes, Treatment response

Jing Hu, Xiujin Yang, Zhiyun Hou. Changes of peripheral blood ISGs and their relationship with curative effect of interferon therapy in patients with HBV infection[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(04): 343-347.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.04.011

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I04/343

Figures/Tables 6

References 19

[1]	Li H, Barbara C, Dominic D, et al. Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates - ScienceDirect[J]. Vaccine, 2020, 38(16): 3255-3260.
[2]	Li CL, Li CY, Lin YY, et al. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region[J]. Hepatology, 2019, 69(2): 498-512.
[3]	Bockmann JH, Stadler D, Xia Y, et al. Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes[J]. J Infect Dis, 2019, 220(4): 567-577.
[4]	Xia YC, Martin S, Volker M, et al. PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice[J]. Antiviral Res, 2019, 161(1): 134-143.
[5]	Chen X, Yue RC, Li XM, et al. Surfactant protein A modulates the activities of the JAK/STAT pathway in suppressing Th1 and Th17 polarization in murine OVA-induced allergic asthma[J]. Lab Invest, 2021, 22(9): 1-10.
[6]	Hubel P, Urban C, Bergant V, et al. A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape[J]. Nat Immunol, 2019, 20(4): 493-502.
[7]	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华内科杂志, 2005, 45(1): 3-15.
[8]	凡豪志, 张云, 岳明, 等. CC趋化因子细胞受体5基因多态性与慢性丙肝干扰素疗效关联性的研究[J]. 中华疾病控制杂志, 2018, 22(10): 1020-1023.
[9]	赖思敏, 赖小丽, 黄汐, 等. 核苷(酸)类似物经治序贯聚乙二醇干扰素治疗慢性乙型肝炎的荟萃分析[J]. 中国感染与化疗杂志, 2019, 24(5): 489-494.
[10]	Yuan W, Huang D, Wu D, et al. Pegylated Interferon-ɑ(IFN-ɑ) Enhances the Inhibitory Effect of Natural Killer Cells on Regulatory T Cells via IFN-γ in Chronic Hepatitis B[J]. J Infect Dis, 2021, 19(4): 216-219.
[11]	Kerr CH, Skinnider MA, Andrews D, et al. Dynamic rewiring of the human interactome by interferon signaling[J]. Genome Biol, 2020, 21(1): 2050-2053.
[12]	陈邦涛, 冯旭娇, 杨青青, 等. 神经前体细胞表达发育调控样基因4在乙型肝炎病毒复制中的作用[J]. 中华传染病杂志, 2020, 38(8): 501-506.
[13]	Millrain M, Chandler P, Dazzi F, et al. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis[J]. J Immunol, 201, 167(7): 3756-3764.
[14]	张小梅, 雷青松, 秦波, 等. 泛素特异性蛋白酶18抑制IFNα抗HBV活性但并不抑制IFNλ抗HBV的活性[J]. 中国生物化学与分子生物学报, 2018, 34(9): 954-961.
[15]	Gruber C, Martin-Fernandez M, Ailal F, et al. Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy[J]. J Exp Med, 2020, 217(5): 319-322.
[16]	Xiang J, Zhang X, Fu J, et al. USP18 Overexpression Protects against Focal Cerebral Ischemia Injury in Mice by Suppressing Microglial Activation[J]. Neuroscience, 2019, 419(11): 121-128.
[17]	Lee K, Jeon J, Kim SJ, et al. 241-LB: Positive Regulation of JAK/STAT at Signaling with SOCS3-Derived Cell-Permeable Binding Domain to ObR Induces Anti-obesity Effect[J]. Diabetes, 2020, 69(1): 241-243.
[18]	王永力, 吴文煜, 尤洁, 等. 核苷(酸)类似物经治慢性乙型肝炎患者干扰素α治疗过程中细胞因子信号抑制因子3的表达与抗病毒疗效的关系[J]. 中华肝脏病杂志, 2019, 27(1): 27-32.
[19]	钟瑞雪, 谢伟贤, 黄泽棋, 等. 干扰素刺激基因表达对Peg-IFN抗乙型肝炎病毒免疫应答的影响[J]. 基因组学与应用生物学, 2019, 38(1): 478-483.

因子	上游引物	下游引物
MxA mRNA	ACAATCAGCCTGGTGGTGGTC	CCTCCCCTACAGTTTCCTCTCC
USP18 mRNA	CTGTGCCATGGAGAGTAGCA	AGGTGGATTGTCAGGGTCTG
SOCS3 mRNA	TGCGCCTCAAGACCTTCAGC	GATGCGCAGGTTCTTGGTCC
GAPDH mRNA	ACATCATCCCTGCCTCTAC	TCAAAGGTGGAGGAGTGG

因子	上游引物	下游引物
MxA mRNA	ACAATCAGCCTGGTGGTGGTC	CCTCCCCTACAGTTTCCTCTCC
USP18 mRNA	CTGTGCCATGGAGAGTAGCA	AGGTGGATTGTCAGGGTCTG
SOCS3 mRNA	TGCGCCTCAAGACCTTCAGC	GATGCGCAGGTTCTTGGTCC
GAPDH mRNA	ACATCATCCCTGCCTCTAC	TCAAAGGTGGAGGAGTGG

组别	例数	MxA mRNA	USP18 mRNA	SOCS3 mRNA
HBV组	80	0.522±0.091	0.059±0.014	1.014±0.213
对照组	80	0.917±0.176	0.016±0.004	0.218±0.037
t		17.831	26.415	32.922
P		<0.001	<0.001	<0.001

组别	例数	MxA mRNA	USP18 mRNA	SOCS3 mRNA
HBV组	80	0.522±0.091	0.059±0.014	1.014±0.213
对照组	80	0.917±0.176	0.016±0.004	0.218±0.037
t		17.831	26.415	32.922
P		<0.001	<0.001	<0.001

组别	例数	性别(例)		年龄(岁,±s)	治疗前丙氨酸转氨酶(Log10 U/L,±s)	治疗前HBV DNA(Log₁₀copies/mL,±s)	肝硬化(例)
组别	例数	男	女	年龄(岁,±s)	治疗前丙氨酸转氨酶(Log10 U/L,±s)	治疗前HBV DNA(Log₁₀copies/mL,±s)	否	是
干扰素应答组	38	21	17	53.87±10.96	2.33±0.14	7.21±0.71	26	12
干扰素无应答组	42	23	19	54.76±11.28	2.31±0.13	7.50±0.92	25	17
t/χ²		0.002		0.357	0.663	1.566	0.683
P		0.964		0.722	0.51	0.121	0.408

Please choose a citation manager

Content to export